Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor

Jorge A Gomez; Diana Caceres; Edisson Rodriguez

doi:10.1080/14737167.2022.1986007

Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor

Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):5-6. doi: 10.1080/14737167.2022.1986007. Epub 2021 Oct 6.

Authors

Jorge A Gomez¹, Diana Caceres², Edisson Rodriguez²

Affiliations

¹ GSK, Buenos Aires, Argentina.
² GSK, Bogota, Colombia.

PMID: 34612137
DOI: 10.1080/14737167.2022.1986007

No abstract available

Keywords: 13-valent pneumococcal conjugate vaccine; Budget impact analysis; Colombia; pneumococcal conjugate vaccination; pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine.

Publication types

Comment

MeSH terms

Colombia
Humans
Pneumococcal Infections* / epidemiology
Pneumococcal Infections* / prevention & control
Pneumococcal Vaccines*
Vaccines, Conjugate

Substances

Pneumococcal Vaccines
Vaccines, Conjugate